B-Cell depletion by anti-CD20 in renal allograft recipients who develop de novo anti-HLA alloantibodies (CCTPT-02/CTOT-02)
收藏官方服务：
资源简介：
The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan, MabThera) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of the transplanted kidney. The pilot study compares the use of rituximab (Rituxan) + site-specific standard immunosuppression to placebo + site-specific standard immunosuppression in the treatment of circulating anti-HLA antibodies in subjects who develop de novo anti-HLA antibodies between 3-36 months after transplant.
提供机构：
ImmPort创建时间：
2016-06-17
